Market Report Focused on Aurora Kinase BAurora 1 or EC 2.7.11.1-Pipeline Review, H1 2016

Aurora Kinase BAurora 1 or Aurora-and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit Aurora Kinase BAurora 1 or Aurora-and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) 
- The report reviews Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AbbVie Inc. Advenchen Laboratories, LLC Aeterna Zentaris Inc. Amgen Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Chipscreen Biosciences Ltd Merck KGaA Nemucore Medical Innovations, Inc. Sanofi Sareum Holdings Plc Vertex Pharmaceuticals Incorporated Vichem Chemie Research Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###